These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34780972)

  • 21. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Bouzari S
    APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escherichia coli FimH adhesins act synergistically with PapGII adhesins for enhancing establishment and maintenance of kidney infection.
    Tseng CC; Lin WH; Wu AB; Wang MC; Teng CH; Wu JJ
    J Microbiol Immunol Infect; 2022 Feb; 55(1):44-50. PubMed ID: 33023843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. d-Mannose Treatment neither Affects Uropathogenic
    Scribano D; Sarshar M; Prezioso C; Lucarelli M; Angeloni A; Zagaglia C; Palamara AT; Ambrosi C
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31941080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.
    Greene SE; Hibbing ME; Janetka J; Chen SL; Hultgren SJ
    mBio; 2015 Jun; 6(4):e00820. PubMed ID: 26126855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs.
    Mashraqi MM; Chaturvedi N; Alam Q; Alshamrani S; Bahnass MM; Ahmad K; Alqosaibi AI; Alnamshan MM; Ahmad SS; Beg MMA; Mishra A; Shaikh S; Rizvi SMD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycosylation changes as important factors for the susceptibility to urinary tract infection.
    Taganna J; de Boer AR; Wuhrer M; Bouckaert J
    Biochem Soc Trans; 2011 Jan; 39(1):349-54. PubMed ID: 21265802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Escherichia coli ST131-
    Liu CM; Stegger M; Aziz M; Johnson TJ; Waits K; Nordstrom L; Gauld L; Weaver B; Rolland D; Statham S; Horwinski J; Sariya S; Davis GS; Sokurenko E; Keim P; Johnson JR; Price LB
    mBio; 2018 Aug; 9(4):. PubMed ID: 30154256
    [No Abstract]   [Full Text] [Related]  

  • 30. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding.
    Zhou G; Mo WJ; Sebbel P; Min G; Neubert TA; Glockshuber R; Wu XR; Sun TT; Kong XP
    J Cell Sci; 2001 Nov; 114(Pt 22):4095-103. PubMed ID: 11739641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
    Langermann S; Möllby R; Burlein JE; Palaszynski SR; Auguste CG; DeFusco A; Strouse R; Schenerman MA; Hultgren SJ; Pinkner JS; Winberg J; Guldevall L; Söderhäll M; Ishikawa K; Normark S; Koenig S
    J Infect Dis; 2000 Feb; 181(2):774-8. PubMed ID: 10669375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation.
    Schwartz DJ; Kalas V; Pinkner JS; Chen SL; Spaulding CN; Dodson KW; Hultgren SJ
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15530-7. PubMed ID: 24003161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis.
    McLellan LK; McAllaster MR; Kim AS; Tóthová Ľ; Olson PD; Pinkner JS; Daugherty AL; Hreha TN; Janetka JW; Fremont DH; Hultgren SJ; Virgin HW; Hunstad DA
    PLoS Pathog; 2021 Jan; 17(1):e1009314. PubMed ID: 33513212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of Expression of Uropathogenic Escherichia coli Nonfimbrial Adhesin TosA by PapB Homolog TosR in Conjunction with H-NS and Lrp.
    Engstrom MD; Mobley HL
    Infect Immun; 2016 Jan; 84(3):811-21. PubMed ID: 26755158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic relatedness of the Escherichia coli fecal population and strains causing urinary tract infection in the same host.
    Bahadori M; Motamedifar M; Derakhshandeh A; Firouzi R; Motamedi Boroojeni A; Alinejad M; Naziri Z
    Microbiologyopen; 2019 Jun; 8(6):e00759. PubMed ID: 30358940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific residues in the N-terminal domain of FimH stimulate type 1 fimbriae assembly in Escherichia coli following the initial binding of the adhesin to FimD usher.
    Munera D; Palomino C; Fernández LA
    Mol Microbiol; 2008 Aug; 69(4):911-25. PubMed ID: 18627459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Luteolin decreases the attachment, invasion and cytotoxicity of UPEC in bladder epithelial cells and inhibits UPEC biofilm formation.
    Shen XF; Ren LB; Teng Y; Zheng S; Yang XL; Guo XJ; Wang XY; Sha KH; Li N; Xu GY; Tian HW; Wang XY; Liu XK; Li J; Huang N
    Food Chem Toxicol; 2014 Oct; 72():204-11. PubMed ID: 25051393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ
    Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.